Susan Moore Explains Oral Oncolytic Nonadherence
Susan Moore Explains Nonadherence to Oral Oncolytics
Susan Moore, RN, MSN, ANP, AOCN® Oncology Nurse Practitioner/Consultant at MCG explains nonadherence to oral oncolytics.
Moore says at this point the majority of evidence comes from women with early stage breast cancer who have been given, for example, a five year regimen of tamoxifen or an aromatase inhibitor that they take after their surgery and any adjuvant chemotherapy that they happen to have. Women tend to fall off those therapies, sometimes as early as two or three years after starting. The incidence of nonadherence increases as a woman goes along in that one to five year range. In patients that are taking imatinib for chronic myelogenous leukemia (CML), it is relatively easy to measure their BCR and see what their level is. That level will more or less indicate whether or not a patient is being adherent. Moore says those are areas where definite evidence is available, but in many other cases the evidence is anecdotal.
Oncology Nurses Provide Patients an Avenue to Supportive Care
July 31st 2025Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
July 31st 2025Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
